Chatham Capital Group Inc. Raises Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Chatham Capital Group Inc. boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 9.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,800 shares of the company’s stock after purchasing an additional 752 shares during the period. Eli Lilly and Company comprises 1.3% of Chatham Capital Group Inc.’s portfolio, making the stock its 19th largest position. Chatham Capital Group Inc.’s holdings in Eli Lilly and Company were worth $6,846,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Lipe & Dalton acquired a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $26,000. Core Wealth Advisors Inc. raised its stake in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares in the last quarter. Tidemark LLC acquired a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $29,000. Frank Rimerman Advisors LLC acquired a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $37,000. Finally, St. Johns Investment Management Company LLC raised its stake in Eli Lilly and Company by 123.3% during the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after buying an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on LLY shares. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. BMO Capital Markets increased their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Bank of America reiterated a “buy” rating and set a $1,000.00 price target on shares of Eli Lilly and Company in a research report on Monday, June 24th. Finally, Truist Financial reiterated a “buy” rating and set a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $812.72.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the sale, the insider now directly owns 97,583,810 shares of the company’s stock, valued at approximately $86,450,473,117.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $885.91, for a total value of $172,732,959.98. Following the sale, the insider now directly owns 97,583,810 shares of the company’s stock, valued at $86,450,473,117.10. The disclosure for this sale can be found here. Insiders sold a total of 789,704 shares of company stock valued at $672,385,964 in the last three months. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $905.38 on Monday. The stock has a fifty day moving average price of $814.40 and a two-hundred day moving average price of $740.86. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The firm has a market cap of $860.48 billion, a P/E ratio of 133.34, a PEG ratio of 1.97 and a beta of 0.41. Eli Lilly and Company has a 1 year low of $434.34 and a 1 year high of $915.54.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm’s quarterly revenue was up 26.0% on a year-over-year basis. During the same period last year, the company posted $1.62 EPS. Research analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.